<DOC>
	<DOC>NCT00407459</DOC>
	<brief_summary>The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.</brief_summary>
	<brief_title>Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Secondary endpoints are to evaluate: - the objective response rate (RR) of the combination; - the toxicity and the safety profile of the combination; - the duration of response (RD) and time to treatment failure (TTF); - the overall survival (OS) - RR, TTP and OS according to baseline plasma VEGF levels (introduced with Amendment 1 dated 8/11/2007)</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven malignant pleural mesothelioma, inoperable, non previously treated with chemotherapy including intracavitary administration PS 01 Measurable and/or evaluable lesions according to RECIST criteria Adequate organ function Uncontrolled hypertension Evidence of bleeding diathesis or coagulopathy Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>